PersonGen BioTherapeutics Wins 2026 Forbes China Industry Leading Enterprise Award for Breakthrough CAR-T Innovation
核心洞察
PersonGen BioTherapeutics received the 2026 Forbes China Industry Development Leading Enterprise award, recognizing its leadership in cell therapy R&D and industrialization.
The company's lead asset PA3-17, the world's first CD7 (搜索)-targeted autologous CAR-T product, achieved an 85% ORR and 95% MRD-negative complete remission rate in Phase I trials for R/R T-ALL/LBL.
PersonGen's Hefei "Super Factory," a nearly 10,000-square-meter GMP facility, represents one of the largest fully automated CAR-T manufacturing bases in the Asia-Pacific region.
On March 18, 2026, at the Bulgari Hotel in Shanghai, PersonGen BioTherapeutics (Suzhou) Co., Ltd. (搜索) was awarded the title of "2026 Forbes China Industry Development Leading Enterprise" at a gala jointly hosted by Frost & Sullivan and Forbes China Group. The recognition highlights PersonGen's market position and comprehensive strength in the research, development, and industrialization of breakthrough cell therapy technologies, placing the company among 86 honored individuals and enterprises at the event.
Founded in Suzhou Industrial Park in 2010, PersonGen has charted a distinctive path in the CAR-T landscape by focusing on indications that remain underserved by existing therapies. The company's core platforms span CAR-T, UCAR-γδT, in-vivo CAR-T, NK cells, and exosomes, forming an integrated industrial system that encompasses R&D, production, and clinical application across oncology and autoimmune diseases.
PA3-17: Pioneering CD7 (搜索)-Targeted CAR-T in T-Cell Malignancies
At the heart of PersonGen's clinical achievements is PA3-17 injection, the world's first CD7 (搜索)-targeted autologous CAR-T product approved for clinical trials. The company tackled the formidable technical challenge of CD7 targeting — a target that has deterred most global teams — through an innovative non-gene-editing strategy. By co-transducing a CD7-CAR lentivirus and a CD7-blocking lentivirus, the approach traps the CD7 protein in the endoplasmic reticulum and Golgi apparatus of T cells, generating CD7-CAR-T cells that do not express CD7 on the cell surface.
Phase I registration trial data underscore the pipeline's potential: PA3-17 demonstrated an objective response rate (ORR) of 85% and a minimal residual disease (MRD)-negative complete remission rate of 95% in patients with relapsed or refractory T-lymphoblastic leukemia/lymphoma (搜索) (R/R T-ALL/LBL). These results stand in stark contrast to the current standard of care, where traditional chemotherapy yields a 5-year survival rate of less than 20% and a long-term survival rate below 10% after relapse.
Hefei "Super Factory": End-to-End Manufacturing at Scale
PersonGen's industrialization platform, PersonGen Anke, operates a nearly 10,000-square-meter GMP-compliant commercial facility within the National Health Big Data Industrial Park in Hefei High-tech Zone. Described as one of the largest fully automated, intelligent CAR-T cell commercial bases in the Asia-Pacific region, the facility houses clinical-grade plasmid and lentivirus production workshops, enabling end-to-end process development and manufacturing capabilities — from plasmids and lentiviruses to final CAR-T cell products.
The strategic value of this fully integrated system extends beyond production capacity. By internalizing core production processes and standardizing manufacturing with fully automated closed systems, PersonGen reduces contamination risks, achieves batch-to-batch consistency, and significantly lowers manufacturing costs. The first patient in the pivotal Phase II clinical trial was dosed in 2025, as the Hefei facility prepares to transition PA3-17 from "world's first" to "world's first accessible."
Next-Generation Platforms: UCAR-Vδ1T and In-Vivo CAR-T
PersonGen's next-generation technology matrix centers on two strategic pillars. The first, UCAR-Vδ1T, leverages Vδ1 T cells — naturally resident immune cells in human tissues with strong homing ability capable of penetrating the solid tumor microenvironment. The company has developed a world-leading CMC large-scale manufacturing process that enables massive ex vivo expansion and cryopreservation of these rare cells while retaining off-the-shelf properties. In April 2025, UTAA09 injection (CD19 (搜索)-targeted UCAR-Vδ1T) received NMPA clinical trial approval, becoming the world's first approved universal off-the-shelf CD19-UCAR-Vδ1T cell product.
The second pillar, in-vivo CAR-T, represents a fundamental reimagining of cell therapy production. By engineering the envelope glycoprotein of lentivirus to specifically target and transduce resting T cells and NK cells directly in patients, the GUIDED platform bypasses the entire ex vivo cell manufacturing step. The first in-vivo cell therapy product, LV009 (搜索) injection, has completed first-patient dosing, marking the leap from "ex vivo customization" to "in-vivo generation."
As the cell therapy field advances toward universal, standardized, and accessible solutions, PersonGen's sixteen-year trajectory — from independent R&D in an uncharted therapeutic area to full-stack infrastructure spanning plasmid production through commercial manufacturing — positions the company at the forefront of the global race for next-generation cell therapies.